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Let's Make the Worldwide
Fight Against COVID
Transformative for Other
Global Threats like TB
Currently, the world is reeling from COVID-19
pandemic. The awareness campaigns to reduce
the spread of this highly contagious virus have
made some impact. The pandemic has affected
us as individuals, communities, countries and
continents. On the hindsight, the pandemic is
teaching us how to prepare ourselves in a
worldwide threat like this. It is heartening to see
a country as diverse as India waking up to the
challenge in a united way both at the
government and citizen level. The efforts to
bring solutions both in terms of treatment and
vaccine have unfolded a few new ways of
collaboration among big pharma, biotech, non-
profit organizations and Governments.
Furthermore, the model of partnership with
manufacturing companies across the globe has
opened another avenue to meet demand and
affordability. The rapid innovation of a novel
vaccine or drug used to be unthinkable during
the pre-COVID era. Can it be a tipping point for
the fight against chronic infectious diseases that
are even deadlier, such as tuberculosis (TB)? Is
this the time to make our efforts towards fight
against TB transformative? I strongly believe so.
Dr. Nibedita Rath, Scientific Director,
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Currently, the world is reeling from COVID-
19 pandemic. The awareness campaigns to
reduce the spread of this highly contagious
virus have made some impact.
Retrospectively, post the epidemic in China
and the loss of more than 3,000 lives;
everybody probably apprehended it
becoming a global threat. But never have
imagined the magnitude to be this big. In a
global economy where the cross-border
business has been the hallmark of success
and survival, lockdowns, travel restrictions,
closure of non-essential services etc. have
become a norm across the globe in the past
six months and still counting. The pandemic
has impacted us as individuals, communities,
countries and continents. On a positive note,
it brought us together to fight and help each
other. It is heartening to see Asian countries
like Taiwan, Singapore and South Korea
showed the world the way by their proactive
measures to contain the spread of the virus
and minimize the casualties. We sincerely
hope this testing phase will pass and we will
be back to normalcy sooner than the later.
On the hindsight, the pandemic is teaching us
how to prepare ourselves in a worldwide
threat like this. Of course, the advent of
technology in terms of electronic media is
playing a vital role in this. The phrases like
‘social distancing’, ‘stay home, stay safe’,
‘self-quarantine’ etc. are not words from
health workers or medical practitioners or
government, they are widely used and
practised by citizens and communities. We
are becoming more and more aware of the
precautionary measures against this novel
coronavirus.
It is heartening to see a country as diverse as
India waking up to the challenge in a united
way both at the government and citizen
level. The efforts to bring solutions both in
terms of treatment and vaccine have opened
up a few new ways of collaboration among
big pharma, biotech, non-profit organizations
and Governments. The ongoing clinical trial
of the coronavirus vaccine that has emerged
from the University of Oxford-AstraZeneca
collaboration is a great example.
Furthermore, the model of partnership with
manufacturing companies across the globe
has opened another avenue to meet demand
and affordability. The rapid innovation of a
novel vaccine or drug used to be unthinkable
during the pre-COVID era.
 
Can it be a tipping point for the fight against
chronic infectious diseases that are even
deadlier, such as tuberculosis (TB)? TB is a
global health problem and has been




standard of care is long and stressful for the
patients leading to non-compliance that
results in drug-resistant TB. Additionally,
social reaction and isolation against TB
patients put unnecessary psychological
pressure on patients to come out and seek
help. While the pharma, government and
non-profit research organizations are
working towards finding novel drugs and
treatment for TB, we as global citizens can
hugely benefit the cause by talking about it.
This magazine is a small effort towards this
direction.
"The efforts to bring solutions both in terms of treatment and vaccine have opened up a
few new ways of collaboration among big pharma, biotech, non-profit organizations and
Governments."
3
There has been concerns and rightly so, that
the COVID-19 pandemic is adversely affecting
the TB services in prevention, case-detection
and management. This might be inevitable
considering the unprecedented pressure the
health care system is facing now and the need
to mobilize the resources.
 
The pragmatic approach however is our
preparedness to deal with this kind of
situation and make sure our long term
commitment to STOPTB
(http://stoptb.org/news/stories/2020/ns20_0
14.html) has not taken a back seat. The article
from Dr. Ansu Bhardwaj in this issue is an eye
opener. At the same time the response from
digital technology to support the communities
and health care system during COVID has
been rapid and innovative. Add the
innovations from big pharma and non-profit
organizations to fight against cancer to our
learning. The article from Dr. Peter Kapitein
from the company Inspire2Live is inspirational
in this regard. The article from Dr. Shailesh
Nayak has emphasized that India needs to
take the lead in developing a strategy to
enhance its efforts to eradicate TB. Dr. V
Bhujanga Rao’s article talks about new
technological intervention such as SAFE
(Satellites for Epidemiology) for better
surveillance of TB. Regarding invention in
treatments, Dr. Urmi Bajpai’s has emphasized
on exploring the possibility of phage therapy
in the battle against drug-resistant TB. Dr.
Rudrodip Majumdar's article has cited the
need for new vaccines towards achieving
Millennium Development Goal of eliminating
TB globally by 2050. Is this the time to make
our efforts towards fight against TB
transformative? I strongly believe so.
"There has been concerns and rightly so,
that the COVID-19 pandemic is adversely





The world health organization has predicted
high mortality rates due to infection by drug-
resistant pathogens and has called for taking
urgent measures to mitigate the crisis (WHO
Report , 2019). While several national and
international bodies have taken initiatives for
finding new antibiotics, a less enthusiastic
R&D by pharmaceutical companies towards
antimicrobial drug discovery has aggravated
the crisis globally. The alarming rate of
occurrence of multidrug-resistant (MDR-TB)
and extensively drug-resistant tuberculosis
(XDR-TB) therefore mandates pacing up the
efforts to discover new drugs as well as
explore alternative options with open mind.
The world health organization has predicted
high mortality rates due to infection by drug-
resistant Mycobacterium tuberculosis and has
called for taking urgent measures to mitigate
the crisis (WHO Report, 2019). While several
national and international bodies have taken
initiatives for finding new antibiotics, a less
enthusiastic R&D by pharmaceutical companies
towards antimicrobial drug discovery has
aggravated the crisis globally. The alarming
rate of occurrence of multidrug-resistant
(MDR-TB) and extensively drug-resistant
tuberculosis (XDR-TB) therefore mandates
pacing up the efforts to discover new drugs as
well as explore alternative options with open
mind.




In this piece, I am aiming to highlight the
role bacteriophages (phages for short) can
play as potential alternative or adjunct to
antibiotics and why higher participation by
the research and the medical community is
required to examine them as effective anti-
mycobacterial agents. Phages are virus of
bacteria and are estimated to be the most
abundant biological entity (1031) on the
planet. They are highly specific predators to
their bacterial hosts and have a benign
presence in the environment. These simple
facts make them a useful and inexpensive
resource for developing new antibacterial
solutions, especially against drug-resistant
chronic infections. Also, the phage-encoded
lytic enzymes such as endolysins,
ectolysins, depolymerases are gaining
attention as potential alternate
/complement to antibiotics (Hatfull et al.,
2012; Fischetti 2018). Bacteriophage therapy
is already being practised in Poland,
Georgia, Russia since about a century (A.
Sulakvelidzeet al., 2001; LL Furfaroet al.,
2018; T Parfittet al.,2005). Recently, a
successful case study from United States
(Schooley et al., 2017) where a terminally ill
patient, suffering from a chronic multi-drug
resistant Acinetobacter baumanii infection
was rescued by phage therapy, has
catalysed the research on clinical
applications of bacteriophages.
Phage/lysin therapy for treating
tuberculosis (TB) doesn't exist so far. The
challenging part of using phages for
treating TB is the intracellular location of
M.tuberculosis (Mtb), which impedes the
targeted delivery of phages. Also, only
limited Mtb-specific lytic phages have been
discovered so far. However, these are not
intractable impediments; a greater number
of Mtb-specific phages should be
discovered and their variants can be created
by genetic engineering to expand their host
range or to meet the other therapeutic
requirements. A major impetus to the cause
came from a recent successful case of
phage therapy against a non-tuberculous
mycobacterial infection (M.abcessus) in a
young patient of cystic fibrosis who had
undertaken lung transplant and had
developed chronic infection and the
prognosis was poor (Dedrick et al., 2019).
This case has served as a convincing proof
of concept and drawn world's notice to the
therapeutic potential of phages in treating
mycobacterial infections. This was also the
first instance, where a cocktail of
genetically engineered mycobacteriophages
(lysogenic genes were edited) were used in
human therapy.
Besides using the whole virulent phages,
the phage-derived lytic enzymes such as
lysins can also be effectively used in the
treatment of bacterial infections. Unlike
standard-of-care antibiotics which are
broad spectrum, endolysins are specific and
hence are safe for the commensal
microflora. Lysins can target drug-resistant
strains with same specificity and
sensitivity. Also, the occurrence of bacterial
resistance against these enzymes is less
probable since bacteria are less likely to
modify peptidoglycan, which is one of the
most essential components of the bacterial
cell wall. For these reasons, a spurt in
interest in phage derived endolysins, also
called as enzybiotics, is being witnessed
and several of them have been scaled up for
commercial purpose (Fischetti, 2018). For
example,  Staphefekt(TM)  is  an  endolysin-
From L to R: Doctor Helen Spencer, Prof. Gram Hatfull, the
patient Isabelle who undertook phage therapy for





ibased aseptic solution (Schmelcher,
Mathias, et al., 2015), manufactured by
Micreos company (Netherlands) and Ecto-
LysinTMP128 is an ectolysin
(Shankaramurthy C. et al., 2017) from
Ganagen Inc. Both the enzymes target skin
infections caused by methicillin
resistantStaphylococcus aureus(MRSA)
Another successful example of a lysin
effective against S. aureusinfections is CF-
301 developed by ContraFect Corporation
(NY, USA)(Schuchet al., 2017). 
Mycobacterial cells have a complex cell wall
(envelop) consisting of a cytoplasmic
membrane and peptidoglycan layer, which is
covalently linked to the arabinogalactan-
peptidoglycan (mAGP) complex and mycolic
acids (Chatterjee 1997). Mycobacteriophages
usually encode two endolysins, Lysin A and
Lysin B, which act on the peptidoglycan
layer and the mycolic acid-arabinogalactan
layer, respectively and help phages lyse the
mycobacterium for the release of viral
progeny. Phages and the endolysins can
also be used synergistically with antibiotics.
The combination can help to treat late-
stage, drug-resistant infection by reducing
the MIC (minimum inhibitory concentration)
and delaying the occurrence of antibiotic
resistance (Kalapala et al., 2020).
Hence, in the grim state of growing
antimicrobial resistance, the natural killers
of bacteria need to be brought in centre-
stage and studied extensively to utilize their
antibacterial potential. By using the modern
tools for culture techniques, phage
purification, high throughput screening, for
genome & proteome analysis and
understanding their pharmacokinetic/
pharmacodynamics, the century-old therapy
can meet the rigours of modern-day
medicine. There is a vast reservoir of
untapped bacteriophages and their derived
lytic enzymes. What is required is to build
repositories of well-characterized lytic
mycobacteriophages and endolysin (natural
and/or    engineered)     specific     to    drug-
sensitive and resistant Mtb strains, devise
efficient phage delivery mechanisms and
develop procedures for effective phage
therapy against tuberculosis. For this to
happen, the scientists, clinicians and
regulatory authorities need to work in
tandem. Ultimately, framing guidelines for
compassionate use of phages/phage-encoded
lysins in treating drug-resistant infections and
clinical trials should not be far-fetched to our
imagination!
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over a three month period. This
translates to a 13% (1,90,000) increase in
TB deaths in 2020, similar to what it was
in 2015. In the second scenario the
detection drops by 50% leading to a 26%
increase in TB mortality, as was in
2012[4]. Irrespective of which scenario
mimics the reality, these estimates
clearly indicate that the pandemic has
caused severe damage to the progress
made in TB control strategies over the
past 2-3 decades.
TB control programs are designed as a
part of the public health systems which
are critically impacted during the
pandemic. The recent WHO reports
highlight the reallocation of TB
resources to COVID-19 testing. Also, the
magnitude of COVID-19 pandemic has
exposed the fragile health care systems
across the world. Recent articles also
highlight the potential risk of
covidization without long term strategic
planning[5]. To maintain the momentum
of TB control programs in the context of
the pandemic, WHO has developed an
accelerated action plan [6]. However, this
requires proactive participation of
stakeholders with clear understanding of
their roles and potential contributions in
the accelerated response framework.
Were we doing enough before the
Pandemic? Looking back in time in the
pre-pandemic era, the issue of patient-
centered care for TB remained unmet.
Patient-centered care refers to all the
aspects from disease diagnosis to
treatment. Several studies in past years
have highlighted the complex route a
suspected TB patient needs to take in
order to receive appropriate diagnosis
and treatment. These studies highlight
the challenges and gaps resulting in
patients not being provided the right
guidance on diagnosis and not being
referred to settings which are equipped
to handle TB diagnosis and subsequent
treatment options. Such gaps in
implementation    of   TB    care   are   the                 
It's Time to Act!!
Awareness of the Stakeholders
Patients Centered Care
Technology driven solutions
The Pandemic has caused severe damage to
the progress made in addressing Tuberculosis.
An interdisciplinary collaborative framework
is needed to address the ongoing and
anticipated pandemics.
"'The Biggest Monster' Is Spreading. And It's Not
the Coronavirus" - This is the title of a recent
article in The New York Times[1]. The article
refers to the unbridled spread of the perennial
Mycobacterium tuberculosis infection that
causes Tuberculosis (TB). Tuberculosis was the
first infectious disease to be declared a global
emergency by WHO in 1993. Ever since countries
have made consistent efforts and developed
novel interventions saving millions of lives.
However, despite the progress made and the
fact that most TB programs have 100% DOTS
(Directly observed treatment, short-course)
coverage, the TB infection management and
treatments are far from adequate[2].
The Pandemic and its Impact on TB
Tuberculosis disease burden in India and rest of
the world demanded a global concerted effort
to develop new treatment and prevention
strategies. This realization led the world
leaders and organizations to come together and
commit to End TB. The proposed strategy of the
End TB mission aims to reduce TB deaths by
95% between 2015 and 2035[3]. However, latest
reports from WHO clearly indicate that the
progress made to achieve this goal has been hit
hard by the COVID-19 pandemic. Two scenarios
have been analyzed to predict TB mortality in
the pandemic context. In the first scenario, it is
estimated that  TB  detection  decreases by  25%
Dr. Anshu Bhardwaj, Senior Scientist, CSIR-
Institute of Microbial Technology, GN
Ramachandran Protein Center, Chandigarh,
India
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reasons for delayed diagnosis and
treatment. A recent study from 30 high-
burden countries shows that one in two TB
patients (50%) successfully complete
treatment[7]. The situation is worse for
DR-TB (drug-resistant -meaning forms of
TB that do not respond to 1 or more
antibiotics) patients. It is reported that
fewer than 1 in 4 individuals with DR-TB
patients receive treatment[8]. This clearly
indicates that coverage does not reflect TB
treatment out comes. The Lancet Global
Health Commission on high-quality health
systems reported that poor-quality care is
a bigger killer than insufficient access to
care[9]. In the Lancet TB Free World report,
the authors recommend patient-centered
services as the top most priority for
achieving better TB control. The report is
based on how the quality of care stands
globally and what specific gaps exist. The
report recommends adopting the HQSS
framework (High-quality health systems in
the Sustainable Development Goals era) to
achieve quality TB care[10]. 
What should we do now? A global
framework with integrated approach is
needed to build public health systems to
expand access and improve the quality of
care in an accelerated mode. Though TB is
one of the major killers in the world from
an infectious agent, there are other drug
resistant infections which are increasing at
an alarming rate and it will not be an
exaggeration to state that all these are
pandemics in the making and have been
recognized as potential pandemics as early
as in 1999[11]. If we do not act now and
address the ongoing and anticipated
pandemics through an integrated approach
the progress made over the last several
decades in addressing the same will be
seriously jeopardized. We therefore need
to look at interventions which engage all
stakeholders in real time. We need to ACT:
Awareness of the Stakeholders
Patient Centered Care Technology
Driven Solutions
New means of generating Awareness are the
need of the hour. These methods should be
engaging as well as provide platforms for
generating evidence of what the grass root
level issues are so as to provide proper Care.
These solutions should be Technology driven
(telemedicine, interactive apps for ecological
momentary assessments, digital DOTS, smart
pill box, etc).The decreasing rate of internet
connection and the expansion of smart phone
availability provides an unprecedented
opportunity for better and precise
management of TB control programs. Last
and the most critical step is to invest in
science of disease biology, development of
new methods of point-of-care affordable
diagnosis, discovery and development of
shorter and targeted treatment regimens,
adoption of evidence based prescription and
use of data analytics in achieving all these
goals in an interdisciplinary collaborative
framework.
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"The World Health Organization (WHO)
data shows that about 10 million
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Brief overview about TB infection:
Tuberculosis, which is also popularly called as
TB, is one of the most ancient diseases that has
stayed and co-evolved continuously with the
human beings, with the earliest record being
more than 17000 years old[1, 2]. TB is caused by
the bacterium named Mycobacterium
tuberculosis. Broadly, TB can be categorized
into two different classes: (a) active disease
and (b) latent infection. The most common form
of active TB is pulmonary TB, but it can manifest
in other organs as well, and those instances are
termed as "extra pulmonary TB"[3]. Depending
on the degree of infection, a person with active
pulmonary TB disease may exhibit the
symptoms like chest pain, cough, phlegm,
weight loss, weakness, fever, chills and
sweating at night; and the active patients are
prone to spreading the disease by coughing the
infectious particles into the air. An aggressive
form of active TB is known as miliary TB, which
may take place if TB bacteria find their way into
the bloodstream. In this rare form, the bacteria
quickly spread all over the body in tiny nodules
and affect multiple organs, leading to the
fatality of the concerned patient[4].
On the other hand, the patients with latent
TB do not develop the overt disease, and in
many of the cases, even the chest x-ray
images may appear to be normal. One
proven and effective way to detect latent
TB is to look for the reaction to the
tuberculin skin test (TST) or interferon-
gamma release assay (IGRA). However, the
latent TB infection in asymptomatic
individuals may escalate to the active
disease at any time during their lives due to
a compromised immune system arising
from other illnesses such as HIV or special
medications (e.g. the medication following
organ transplants to prevent organ
rejection)[5, 6]. To curb this TB escalation,
the United States devised a preventive
therapy for latent TB infection. Vaccination
for TB has always been inadequate, as only
one vaccine (Bacille Calmette-Guérin (BCG)
TB vaccine) developed way back in 1921 is
available for helping the immune system
towards developing necessary protection
from the disease. The vaccine is usually
administered to the infants of the at-risk
populations. In some of the advanced
countries, like the United States, BCG
vaccine is not generally recommended as
variable effectiveness of the vaccine has
been found against adult pulmonary TB,
and there is a chance of the vaccine's
potential interference with TST
reactivity[7].
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The emergence of drug-resistant
tuberculosis (DR-TB): With the advances in
the mainstream medical sciences, the
number of reported tuberculosis patients
experienced a decline. Further, the ability to
treat some forms of TB effectively with
drugs led to the collective perception
amongst the general population, as well as,
the medical community that TB is no longer
a disease of morbidity and mortality.
However, the recent discovery of multidrug-
resistant tuberculosis (MDR-TB) in the US-
American centres for the HIV patients, as
well as, in a few other countries that
regularly sees a large influx of migrants
with TB syndromes, highlights the
importance of continued research and
innovation towards curbing the TB
outbreak[6]. The World Health Organization
(WHO) data shows that about 10 million
people were infected with TB in 2017, and
about 1.6 million succumbed to the disease.
Data-based evidence brought forth 558,000
new cases with TB infection that exhibited
resistance to the most effective first-line
antibiotic. Among the patients with drug-
resistant TB, about 82% were resistant to
multiple antibiotics[8]. Therefore, we should
get rid of the sense of complacency and
large-scale research should be directed
towards the innovation of an effective drug,
as well as, an advanced treatment regimen. 
Treatment Regimen for TB and Recurrence
of Infection: The prevalent treatment
regimen for the infected people is quite
lengthy with tuberculosis symptoms lasting
for a duration of six months to a year, and
sometimes even more for the drug-resistant
TB variants[9]. Relapse of TB for people
undergoing treatment is also very common,
as many of the patients fail to stick with the
daily schedule of medications that typically
comprises of multiple pills[9]. Recurrence of
TB infection may arise due to multiple
reasons. Data show that the trends and
signatures are also specific to the
geographical locations in this context. For
example, in the United States and Canada,
most of the recurrent tuberculosis cases
were found to  be  a  relapse  of  the  original
infection, presumably because of the
insufficient treatment; whereas, in a study
done in the TB-prone city of Cape Town in
South Africa, 18% of the 612 participants
exhibited tuberculosis reinfection and 14%
of those patients were infected again with a
different strain of TB following a successful
treatment[9].
Latest Advancements in the Research:
Recently, in a clinical trial conducted on the
3,330 participants living in active
tuberculosis disease centres in Kenya,
South Africa, and Zambia, doses of the
Glaxo SmithKline inoculation called
M72/AS01E was administered. The vaccine
trial was found to have a 50% efficacy rate.
However, William Schaffner, an infectious
disease specialist and a professor of
preventive medicine and health policy
affiliated with the Vanderbilt University
School of Medicine in Nashville, Tennessee
mentioned that the scaling up of such
research activities is required, and the
vaccine will not be available to the public
for at least a decade or so[10]. In another
major effort in 2019, a team of researchers
at RCSI (Royal College of Surgeons in
Ireland), funded by the Health Research
Board (HRB) and the Royal City of Dublin
Hospital Trust, claimed to have developed
small, safe-for-consumption particles
packed with all trans-retinoic acid (atRA), a
derivative of Vitamin A, so that they can be
used in an inhaler. Upon being inhaled by a
patient, the atRA-loaded particles would
reduce the load of TB bacteria in the lungs
and improve the patient's immune system
leading to an increased chance of
recovery[8]. In a further advanced study at
the University of Michigan, Artificial
Intelligence (AI) is being used to create a
software tool to enable prediction of
suitable combinations of pharmaceutical
drugs, from the pool of both likely, as well
as, unlikely candidates, to facilitate more
effective treatments without requiring
exhaustive clinical trials that are typically
time-consuming[11].
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"About 25% of total TB
patients are in India and 600
people on an average die
from TB every day. At the
same time, TB is curable and
preventable."
Looking at these recent advancements, it
would be reasonable to conclude that along
with malaria, HIV, and universal flu vaccine,
an effective TB vaccine is going to be a major
discovery and such a breakthrough innovation
could prevent many serious illnesses and
reduce the mortality that is owed to the
insufficient medical intervention.
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Awakening to Crises of the TB
Endemic
Tuberculosis or TB is one of the major causes
of death worldwide. India is worst affected,
followed by China, Indonesia, the Philippines,
Pakistan, Nigeria, Bangladesh and South
Africa. About 25% of total TB patients are in
India and 600 people on an average die from
TB every day. At the same time, TB is curable
and preventable. The death rate in India is
falling due to improved diagnosis and
treatment, though slowly. We have a long way
to go before we can eliminate TB endemic by
2025, a target set by India.
The recognition of the elimination of TB as one
of the sustainable development goals is a
testimony of its importance to humanity. The
goal of the free world from TB has to be linked
with other sustainable developmental goals as
well. The most important goal in this regard
relates to ending poverty from the world. Each
human being should get adequate support for
fulfilling its basic needs. Balanced economic
growth and inclusive growth are key to reduce
poverty. Improved nutrition to the poorest is
vital as undernourished are at increased risk,
almost three times more. Access to affordable
health care for early diagnosis and treatment of
TB patients is another critical issue. The
'Aayushman Bharat' program is the right step in
this direction. The National Tuberculosis Control
Program has also focused on increasing access
to health care for TB patients.The current
standard of care is long and stressful for the
patients leading to non-compliance that result
in drug-resistant TB. Other socio-economic
conditions, availability of clean fuel for cooking,
air pollution, unemployment, poor built-
environment and crowding in homes and lack of
awareness especially among women need to be
addressed at the earliest. Most patients are
socially marginalized people. Dis-empowerment
and stigma put unnecessary psychological
pressure on patients to come out and seek help.
Dr. Shailesh Nayak, Director, National
Institute of Advanced Studies, Bengaluru
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Tuberculosis: The Quest for a
Better Approach
As a patient advocate from Inspire2Live, the
Dutch and international organization of
patient advocates that aims to get cancer
under control, it's not a weird question to
write an article about tuberculosis. It is
particular not weird because I was asked about
how to come to a better approach of setting up
research for a better treatment of
tuberculosis. To be honest, I know almost
nothing about tuberculosis. I know a lot about
cancer and about how to organize settings,
workshops and brainstorm sessions for
realizing new approaches to deal with it. I'm
convinced it works for other diseases as well.
We call our approach 'The Discovery
Network'(DN). Let's see how this goes.
For the man with a hammer the whole world
looks like a nail. When you never deal with other
people, opinions, businesses and approaches,
you will be convinced of yourself and find out
that you can do the same thing over and over
again and that you are always right. However,
people around you see no chance and even
worse, no progress at all. Arguments like
'change needs time' are needed to justify your
way of working. When dealing with diseases this
is not the right thing. In healthcare, we have a
strong responsibility, we need change and
progress.
People don't want to change. They talk about it a
lot and adapt. But they only adapt when there is
an urgency. And that's what lacking in the
decision-making process in healthcare: there is
no urgency. We say there is and that the patient
is important, but we do not act upon it. The
approach that Inspire2Live chose for
improvement in treatments and change the way
science works is to combine emotions with
arguments. The emotions come from our fellow
patient advocates; they are sick and dying. This
brings   the    urgency   we    need:   better   hurry 
Dr. h.c. Peter Kapitein, Patient Advocate,
Inspire2Live, Amsterdam
India, recently, has eradicated polio, by
very innovative approaches for reaching to
each and every chi ld. Similarly, India needs
to take a lead in developing a strategy to
greatly enhance its efforts to eradicate TB.
One of the most important steps is to
develop an information system based on
GIS for monitoring and reporting each and
every case and how the implementation of
the national program is being carried out at
local, state and district levels.Adequate
investment in research and innovation for
developing affordable drugs, providing
access to diagnosis, treatment, care and
research has to be ensured. Though India
has almost quadrupled its funding from Rs
800 to Rs 3300 crore during 2016 to 2018, It
may need more than Rs 10,000 crore per
year to achieve the target. India has to
show great political will and involve all
stakeholders, pharma companies, civi l
society and the private sector and commit
themselves towards achieving the task of
eradication of TB. I am sure this magazine
is a small but very critical effort towards
realizing this goal. My compliments to them
and wish very best for this noble initiative.
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because we're dying. With emotions alone we
did not get where we want to be. We need
arguments: science, knowledge and facts.
Patient advocates need to know what they
talk about when working with the
stakeholders in the Medical Industrial
Complex: patient organizations, doctors,
scientists, industry, government and health
insurance.
When working on change and improvements
we have to keep 4 maxims in mind. Let me
explain (Reference 1).
Bring a range of people together
Invite someone who does not understand your field
of expertise, but who is smart. Ask her to ask
questions that you have never thought about
before and look for the answer. You will be amazed
by your lack of knowledge in your own field. You'll
be amazed how much you take for granted, but
what (for an outsider) is not self-evident. 'I don't
know who discovered the water but it certainly
wasn't the fish.' And always elicit someone's
opinion: 'I want your opinion, even if I do not like it.'
We are looking for the truth and for that everything
has to be on the table.
Look for the real cause
'Johnny fits into the trouser. The trouser fits into
the bag. Therefore, Johnny fits into the bag.' This is
the logical fallacy of assuming the conclusion. This
statement is clearly nonsense, but in practice there
is often evidence that could hardly, if at all, be
called evidence. I am referring to the fumbling with
data that supports scientific articles and that in a
number of cases simply is neither verifiable nor
repeatable. Continue and ask penetrating questions
(with the various people and their diverse
backgrounds) as far as irritation point and the pain
threshold, and beyond. Only once we know the real
cause is a solution really possible.
Upscale Quickly 
Think big, start small and upscale quickly. You
don't solve cancer by thinking small. Cancer is
a global problem and that requires great
ideas, grand theories and sweeping
approaches. This piece of knowledge comes
from France, that insight from an American.
And look what an essential contribution India
is making on this point.
Be independent 
We are never independent, because we
always act because of something or someone.
The only permissible dependency that
stakeholders have in healthcare is
dependence on the patient. In this, we must
be vigilant. If we see otherwise, then it is our
duty to correct it. All those involved in the
Medical Industrial Complex must ask
themselves seriously whether this is the only
permissible dependency, or whether there is
another dependency at play. Everyone is
obliged to answer this question in good faith
and to weigh up that answer in the
discussions they have with the other parties
concerned about the patient's problems: 'Am I
serving you or someone else?' The four
maxims help in determining the right route to
reach a solution. And the nice thing is that
they are placed in a certain order in which the
various points influence and reinforce each
other in their application. You bring together
different people with different opinions, who
jointly search for the real solution and find it.
What they find must then be brought to all
patients as quickly as possible. This solution
can only be found and implemented if there
are no interests at play other than those of
the patient. 
The DN concept 
The DN creates an open environment for
those who are in this structure to pursue a
common goal and to better reach that
common goal. Patients are an integral part of
this open environment. The DN will facilitate
at least three levels of cooperation in the
area of research and treatment. 
- Better sharing of better observations 
- Better utilization of better treatments 
- Better organization of better networks 
To function as a full-blown information
science, with connected brains, the DN must
incorporate all levels of cooperation. An
inherent problem in this kind of system is that
the DN must enable the need for both
openness to novelty and closure when
disciplined research and/or treatment
regimens are required. 13
Without better sets of high quality
observations of groups and individual
patients, better treatments will not be
discovered and utilized. In fact, without
capturing better quality data of treatment
effects and sharing them, we will not be
able to distinguish good from bad, better
from worse or better from really better. At
some point, strict regimens of diagnostics,
treatment and observation of treatment
effects are necessary to make progress at. 
At the end of the day, treatments are
central. Introducing better treatments also
means adapting existing regimens and
replacing existing regimen with better
regimen at the level of well-defined groups
and in given cases, at the level of the
individual patient. 
But we also need better networks (research
groups, cooperating institutes, teams of
clinicians and lab researchers, et cetera).
We need to change the way we work within
and between groups of researchers,
physicians, engaged patient and all relevant
others. Here data sharing and the fluent
creation of problems focused networks of
researchers, clinicians and engaged patients
is crucial. 
What is needed is a kind of hub connecting
the relevant people and professionals, and
this is the instrumental reason for creating
the DN. The DN is about the discovery of
better treatments: for groups and for
individual patients. This needs better
organization!
The functions of the DN 
What is the DN? The basics are simple. The
implementation and the use will be a lot harder
to specify. In fact, actual use is a discovery
process in itself. We enter the world of
information science, because apart from the
actual brains of people and the hardware,
everything else should become exchangeable as
information! 
1. The first element: The basic idea is that we
create a network, which supports the
combination of ideas. This means: connecting
brains and sharing all information that the
brains need to reach the goal. 
2. The second element relates to better
observations. High quality characterizations will
be needed. New imaging regimens, new imaging
techniques, better reports and access to
repositories will be necessary. 
3. We need a map of all possibilities of
treatments. 
4. We need exchange with and connection to
networks of scientists and clinicians. The
networks include the people who operate the
facilities to design animal models, screen drugs
and set up trials. 
5. Observations, treatments and networks must
be matched. This is qua interfacing and
technically the most challenging part. Human
intervention will be required to get the details
right. Only users from the proper networks will
have the knowledge to make the right decisions.
6. Results must be studied in populations of
patients and must also feed back into the DN.
Brokerage and closure 
Improvement ultimately means discovery,
invention, development and implementation.
Quality new observations,, treatments and
networks will have to be added to or replace the
old sets of observations, treatments and
networks. Brokerage and closure is about this
dynamic process of improvement. The DN is an
improvement system; ever open to
falsifications, replacement of entrenched
practices and better ways of working. To
improve the system of discovery and speed up
implementation for patients, we have to expand
on  the  boundaries  of  observations, treatments
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"TB, as we all know, is the most infectious disease on this planet killing
more than 2 million people each year."
and networks. The DN connects brains and
leaves to the brains what the brains are good
at. It lets the network do what the network is
good at. If the DN is based on any trick, this
is its basic trick. It is not an Artificially
Intelligent system. The Intelligence is in the
interaction between brains of real people. If
the people stop thinking and stop
interacting, it will not make any difference at
all. And this brings us to the human factor.
The most important factor of all!
The central position of the human factor 
The patient of the 21st century makes the
importance of the patient perspective very
clear (Reference 3). At the core, it is the
patient who must benefit and who is
smothered, because of regulations, the
reputation of pharma, bad information,
deliberate misrepresentation of research
results (for example, reporting relative
improvements in percentages instead of real
improvements in terms of absolute
numbers), et cetera. The human factor is the
rate-limiting step. If we succeed to engage
patients, funders, physicians and
researchers, we make progress.
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Tuberculosis Free World
It gives me immense pleasure to
wholeheartedly greet all the medical
professionals, paramedical staff, researchers,
patients etc. on this 'World TB Day being
celebrated every year on 24 March'.
TB, as we all know, is the most infectious
disease on this planet killing more than 2 million
people each year. This communicable disease
caused by Mycobacterium tuberculosis exists on
earth since time immemorial and is intelligent
enough to evade the eradication despite
sustained effort and improvement in medical
sciences. 
Be its Mars mission, building a nuclear
submarine or robotic surgery or weapons of
mass destruction or the advanced jet engine or
eradication of plague, polio, smallpox, human
being has displayed his extraordinary ingenuity
taking every challenge in his stride. Despite
thousands of researchers working for the last
60 years around the globe, the disease is
continued to be a threat to humanity. It takes
about 2 weeks for diagnosis with an increase in
complexity when we come across XDR or MDR
TB cases.
The need of the hour is to relook at our efforts,
redirect our research, utilize advanced
technologies and find out a long lasting solution
to eradicate this disease. Resistance to current
drugs asks for new drugs and hence innovation
in drug discovery. Additionally, TB patients
suffer from social stigma, daunting and difficult
treatment, lack of social support, lack of
motivation to undergo prolonged treatment
resulting in large unsuccessful outcomes.
Dr. V. Bhujanga Rao, FNAE, ISRO Chair
Professor, National Institute of Advanced
Studies, Bengaluru
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Some of the challenges are not medical but
behavioural leading to non-adherence to
treatment. Failure to early diagnosis and
unable to initiate on time effective treatment
are some other which are indispensable for
effective TB control. Expediting research
using point of care Nano bio sensing based
technologies which have the potential to
detect even MDR TB cases with instantaneous
results will be in order.
Today India has set up excellent Nano-,
biotechnology centres that should be funded
to undertake this research at a larger scale.
Nanotechnologies are successful in drug
delivery at site of action which can give
nullify the challenge associated with poor
absorption, metabolism and hence dosage and
duration of treatment. To overcome some of
the patient non-compliance and behavioral
issues, digital platforms and social media can
be used to create interactive communication
between patients, doctors, social workers,
psychologists and researchers. This may
improve the awareness and hence the
adherence to the treatment regimen.
India despite seriously engaged with control
of TB over the last 50 years faces a mortality
rate of 1200 per day. It is gratifying that GOI
has set up a national programme under the
chairmanship of our honourable Prime
Minister and drawn up a framework to create
TB free India.
ESA has funded a project SAFE (satellites for
Epidemiology) which was employed for
routine surveillance of TB in Georgia. This
enabled better follow up of MDR cases. This
has been used by Georgia national centre for
TB to decentralize the way the data was
collected than any other means. We can
probably ask for support from ISRO to initiate
such a programme in India. At the
international level, the WHO has drawn up
strategies at a global level to save the world
from the scourge of TB by 2035 with 90
percent reduction in incidence, 95 percent




or to contribute, please
contact
nibedita.rath@ospfound.org
or visit
www.ospfound.org 
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